Dr. Reddy's Laboratories Limited — Updates, 15-07-2026: General Updates
15-07-2026 | 04:25 pm
15-07-2026 | 04:25 pm
Dr. Reddy's paused Semaglutide injection supply due to API impurity detected during manufacturing scale-up. Expects resolution by September, targeting 6-7 million pens in FY27 Q3/Q4. No patient safety concerns or existing regulatory filing impact. Anticipates an inventory write-down.
No comments yet. Be the first to comment!
